Market Analysis and Assessment for Key Neurodegenerative Disorder Therapies.LYON, France -- Reportlinker.com announces that a new market research report related to the world wide pharmaceutical market is now available to its catalogue. The Global Market and Future Outlook for Neurodegenerative Disorder neurodegenerative disorder Neurology A chronic progressive neuropathy characterized by selective and generally symmetrical loss of neurons in motor, sensory, or cognitive systems Types by area Cerebral cortex–Alzheimer's disease, Pick's disease, Lewy body Therapies 2007 www.reportlinker.com/p045250/neurodegenerative-therapies.html With a market size of US$14.5 billion in 2005 and an anticipated value of US$16.5 billion in 2006, the neurodegenerative market represents a valuable, fast-growing opportunity in the pharma/biotech industry. An increase in the number of aged people, increased life expectancy Life Expectancy 1. The age until which a person is expected to live. 2. The remaining number of years an individual is expected to live, based on IRS issued life expectancy tables. , unmet clinical needs together with advances in treatments of neurodegenerative diseases neurodegenerative diseases diseases characterized by neurodegeneration. Lesions are microscopic only but in chronic disease with massive involvement there may be grossly visible atrophy of affected nervous tissue. , such as Alzheimer's and Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. will continue to contribute to the expansion of the global market. This report provides an insight into the neurodegenerative market, neurotherapeutic drugs currently available, and upcoming products. This report specifically focuses on key CNS See Continuous net settlement. CNS See continuous net settlement (CNS). diseases, such as Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. , Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis amyotrophic lateral sclerosis (ALS) (ā'mīətrōf`ik, sklĭrō`sĭs) or motor neuron disease, , Huntington's disease Huntington's disease, hereditary, acute disturbance of the central nervous system usually beginning in middle age and characterized by involuntary muscular movements and progressive intellectual deterioration; formerly called Huntington's chorea. , and neuropathies. Profiles of leading companies that are active in R&D in these areas are included.The report presents, in detail, an overview of the current global market for neurodegenerative drugs for selected neurological diseases, including currently marketed and forthcoming neurotherapeutic products. Market analysis and assessment for key neurodegenerative therapies is done across major pharmaceutical markets in United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. (US)/North America, Europe and Japan. Key features of this report: * Statistical information for selected neurological diseases * Overview of the disease, key therapies, market size and growth, market composition by region, as well as market outlook and forecast * Global sales figures sales figures npl → cifras fpl de ventas for key neurodegenerative therapies * Financial forecasts by disease and key product * Description of neurotherapeutic products currently on the market, including a description of products in the pipeline * Company profiles of major pharmaceutical providers active in R&D in these areas * The report also deals with factors affecting growth, new drug therapies, and clinical research in the completion stages. The diseases/conditions addressed in the report include: * Alzheimer's disease * Parkinson's disease * Multiple sclerosis * Amyotrophic lateral sclerosis * Huntington's disease * Neuropathies Table of content 1 Executive Summary 1.1 Report Scope 1.2 Definitions 1.2.1 Alzheimer's Disease 1.2.2 Parkinson's Disease 1.2.3 Multiple Sclerosis 1.2.4 Amyotrophic Lateral Sclerosis 1.2.5 Huntington's Disease 1.2.6 Neuropathies 1.3 Report Methodology 1.4 The Market 1.5 Market Composition 1.6 Competitive Profiles 1.7 Factors to Growth 2 The Market 2.1 Global Pharmaceutical Market 2.2 Global Neurodegenerative Market 2.3 Market Size and Growth 2.4 Market Composition 2.5 US/North American Market 2.5.1 Overview 2.5.2 US Neurodegenerative Market 2.5.3 Canadian Neurodegenerative Market 2.5.4 Regulatory Scenario 2.6 European Market 2.6.1 Overview 2.6.2 Regulatory Scenario 2.7 Japanese Market 2.7.1 Overview 2.7.2 Japanese Neurodegenerative Market 2.7.3 Regulatory Scenario 3 Market Composition: Alzheimer's Disease 3.1 Overview 3.2 Risk Factors 3.3 Symptoms 3.4 Therapies 3.5 Market Size and Growth 3.6 Market Composition 3.7 By Region 3.8 Major Players 3.9 Anti-Alzheimer's Disease Products 3.9.1 AChE inhibitors 3.9.2 NMDA Antagonists 3.10 Incidence of Alzheimer's Disease 3.11 In the Pipeline 3.12 Looking Ahead 3.13 Key Clinical Trials 3.14 Key Emerging Therapies 3.15 Research and Development Trends 4 Market Composition: Parkinson's Disease 4.1 Overview 4.2 Risk Factors 4.3 Symptoms 4.4 Therapies 4.5 Market Size and Growth 4.6 Market Composition by Region 4.7 Major Players 4.8 Anti-Parkinson's Disease Products 4.8.1 Anticholinergics 4.8.2 COMT Inhibitors COMT inhibitors Drugs that block catechol-o-methyl transferase, an enzyme that breaks down dopamine. COMT inhibitors include entacapone and tolcapone. Mentioned in: Parkinson Disease 4.8.3 Combination Anti-Parkinson's Agents 4.8.4 Dopamine Receptor Dopamine receptors are a class of metabotropic G protein-coupled receptors that are prominent in the vertebrate central nervous system (CNS). The neurotransmitter dopamine is the primary endogenous ligand for dopamine receptors. Agonists 4.8.5 Carbidopa Levodopa levodopa: see l-dopa. levodopa or L-dopa Organic compound (L-3,4-dihydroxyphenylalanine) from which the body makes dopamine, a neurotransmitter deficient in persons with parkinsonism. Preparations 4.8.6 MAO-B inhibitors MAO-B inhibitors Inhibitors of the enzyme monoamine oxidase B. MAO-B helps break down dopamine; inhibiting it prolongs the action of dopamine in the brain. Selegiline is an MAO-B inhibitor. Mentioned in: Parkinson Disease 4.8.7 Amantadine amantadine /aman·ta·dine/ (ah-man´tah-den) an antiviral compound used as the hydrochloride salt to treat influenza A; also used as an antidyskinetic in the treatment of parkinsonism and drug-induced extrapyramidal reactions. 4.9 Incidence and Prevalence of Parkinson's Disease 4.10 In the Pipeline 4.11 Looking Ahead 4.12 Key Clinical Trials 4.13 Key Emerging Therapies 4.14 Key Types of Therapies in Development 5 Market Composition: Multiple Sclerosis 5.1 Overview 5.2 Risk Factors 5.3 Symptoms 5.4 Therapies 5.5 Market Size and Growth 5.6 Market Composition 5.7 Major Players 5.8 Multiple Sclerosis Products 5.8.1 Avonex 5.8.2 Betaseron 5.8.3 Rebif 5.8.4 Copaxone 5.8.5 Novantrone 5.8.6 Symptomatic Relief symptomatic relief (sim·t  ·maˑ·tik r 5.9 Incidence of Multiple Sclerosis 5.10 In the Pipeline 5.11 Looking Ahead 5.12 Key Emerging Therapies 5.13 Key Late-Stage Clinical Therapeutics 5.14 Key Clinical Trials 6 Market Composition: Amyotrophic Lateral Sclerosis 6.1 Overview 6.2 Risk Factors 6.3 Symptoms 6.4 Therapies 6.5 Major Players 6.6 Anti-Amyotrophic Lateral Sclerosis Products 6.7 Incidence of Anti-Amyotrophic Lateral Sclerosis 6.8 In the Pipeline 6.9 Key Emerging Therapies 6.10 Key Clinical Trials 7 Market Composition: Huntington's Disease 7.1 Overview 7.2 Risk Factors 7.3 Symptoms 7.4 Therapies 7.5 Market Size and Growth 7.6 Market Composition by Region 7.7 Major Players 7.8 Anti-Huntington's Disease Products 7.8.1 Neuroleptics Neuroleptics Any of a class of drugs used to treat psychotic conditions. Mentioned in: Stuttering, Tardive Dyskinesia 7.8.2 Benzodiazepines Benzodiazepines Definition Benzodiazepines are medicines that help relieve nervousness, tension, and other symptoms by slowing the central nervous system. Purpose Benzodiazepines are a type of antianxiety drugs. 7.9 Incidence of Huntington's Disease 7.10 In the Pipeline 7.11 Key Emerging Therapies 8 Neuropathies 8.1 Overview 8.2 Risk Factors 8.3 Symptoms 8.4 Therapies 8.5 Market Size and Growth 8.6 Anti-Neuropathies Products 8.6.1 Anticonvulsants Anticonvulsants Drugs used to control seizures, such as in epilepsy. Mentioned in: Antipsychotic Drugs, Osteoporosis 8.6.2 Antidepressants Antidepressants Medications prescribed to relieve major depression. Classes of antidepressants include selective serotonin reuptake inhibitors (fluoxetine/Prozac, sertraline/Zoloft), tricyclics (amitriptyline/ Elavil), MAOIs (phenelzine/Nardil), and heterocyclics 8.6.3 Analgesics Analgesics Definition Analgesics are medicines that relieve pain. Purpose Analgesics are those drugs that mainly provide pain relief. 8.6.4 Others 8.7 Incidence of Neuropathies 8.8 In the Pipeline 8.9 Looking Ahead 8.10 Key Emerging Therapies 8.11 Key Clinical Trials 9 Competitive Profiles 9.1 Amarin 9.1.1 Product Pipeline 9.1.2 Key Financials 9.2 AstraZeneca 9.2.1 Product Portfolio 9.2.2 Product Pipeline 9.2.3 Key Financials 9.3 Avanir 9.3.1 Product Portfolio 9.3.2 Product Pipeline 9.3.3 Key Financials 9.4 Avigen 9.4.1 Product Pipeline 9.4.2 Key Financials 9.5 Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec 9.5.1 Product Portfolio 9.5.2 Product Pipeline 9.5.3 Key Financials 9.6 Boehringer Ingelheim 9.6.1 Product Portfolio 9.6.1.1 Key Financials 9.7 Daiichi Sankyo 9.7.1 Product Portfolio 9.7.2 Key Financials 9.8 Eisai 9.8.1 Product Portfolio 9.8.2 Product Pipeline 9.8.3 Key Financials 9.9 Elan 9.9.1 Product Portfolio 9.9.2 Product Pipeline 9.9.3 Key Financials 9.10 Eli Lilly Eli Lilly can refer to:
9.10.1 Product Portfolio 9.10.2 Product Pipeline 9.10.3 Key Financials 9.11 Forest Laboratories 9.11.1 Product Portfolio 9.11.2 Product Pipeline 9.11.3 Key Financials 9.12 Genzyme 9.12.1 Product Pipeline 9.12.2 Key Financials 9.13 GlaxoSmithKline 9.13.1 Product Portfolio 9.13.2 Product Pipeline 9.13.3 Key Financials 9.14 Guilford Pharmaceuticals/MGI Pharma 9.14.1 Product Pipeline 9.14.2 Key Financials 9.15 IVAX IVAX Industrial Vax (Dec Computer) 9.15.1 Product Portfolio 9.15.2 Key Financials 9.16 Johnson & Johnson 9.16.1 Product Portfolio 9.16.2 Product Pipeline 9.16.3 Key Financials 9.17 Kyowa Hakko Kogyo 9.17.1 Product Portfolio 9.17.2 Product Pipeline 9.17.3 Key Financials 9.18 Lundbeck 9.18.1 Product Portfolio 9.18.2 Product Pipeline 9.18.3 Key Financials 9.19 Merck KGaa 9.19.1 Product Portfolio 9.19.2 Product Pipeline 9.19.3 Key Financials 9.20 Mitsubishi Pharma 9.20.1 Product Portfolio 9.20.2 Product Pipeline 9.20.3 Key Financials 9.21 Novartis 9.21.1 Product Portfolio 9.21.2 Product Pipeline 9.21.3 Key Financials 9.22 Pain Therapeutics 9.22.1 Product Pipeline 9.22.2 Key Financials 9.23 Pfizer 9.23.1 Product Portfolio 9.23.2 Product Pipeline 9.23.3 Key Financials 9.24 Prestwick Pharmaceuticals 9.24.1 Product Pipeline 9.25 Roche 9.25.1 Product Pipeline 9.25.2 Key Financials 9.26 Sanofi-Aventis 9.26.1 Product Portfolio 9.26.2 Product Pipeline 9.26.3 Key Financials 9.27 Schering AG 9.27.1 Product Portfolio 9.27.2 Product Pipeline 9.27.3 Key Financials 9.28 Shire Plc 9.28.1 Product Portfolio 9.28.2 Product Pipeline 9.28.3 Key Financials 9.29 Solvay 9.29.1 Product Portfolio 9.29.2 Product Pipeline 9.29.3 Key Financials 9.30 Takeda 9.30.1 Product Pipeline 9.30.2 Key Financials 9.31 Teva 9.31.1 Product Portfolio 9.31.2 Product Pipeline 9.31.3 Key Financials More market research reports? Go to http://www.reportlinker.com |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion